Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care

Girard et al. report a retrospective, single-centre, real-world study evaluating hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease in Quebec. Hydroxyurea was associated with reduced vaso-occlusive crisis composite events, mostly mild adverse events and no observed hyperviscosity-related complications, while highlighting adherence and prescription-renewal barriers in routine care. Commentary on: Girard et al. Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec. Br J Haematol 2026 (Online ahead of print). doi: 10.1111/bjh.70622.